ASX ANNOUNCEMENT

17 October 2022

DIRECTOR RESIGNATION

Probiotec Limited (ASX:PBP) ("Company") advises that Mr Paul Santoro has submitted his resignation as a Non-Executive Director, effective as of today's date.

Mr Santoro has advised that due to his full-time commitments as CEO of Cygnett and business interests outside of his role with the Company he can no longer commit the necessary time to continue as a Non-Executive Director of the Company.

Probiotec Chairman, Mr Jonathan Wenig stated 'on behalf of the board, I would like to thank Paul for his contribution and service to the Company and wish him the best for his future endeavours'.

---ends---

About Probiotec

Probiotec Limited is a manufacturer, packer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer goods. The company owns six manufacturing facilities in Australia and distributes its products both domestically and internationally. Products are manufactured by Probiotec on behalf of a range of clients, including major international pharmaceutical companies.

Further details about Probiotec are available at www.probiotec.com.au

Authorised for release to the ASX by the board of directors.

For further information contact:

Wes Stringer Chief Executive Ph: (03) 9278 7555











